DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ftjrts/global_orphan) has announced the addition of the "Global Orphan Cancer Drug Market & Clinical Pipeline Insight" report to their offering.
The drug development strategies of the pharmaceutical companies is undergoing a paradigm shift from manufacturing traditional essential medicines to orphan drugs due to significant competition from generics and the associated economic situation. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.
The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols. Inspite of pharma companies facing many obstacles in this field, this segment of orphan drugs is likely to have the potential to provide the key to recovery and stability within the market.
Oncology has emerged as the most promising and revenue generating segment of global orphan drug market in recent years. A major reason for such a high level of concentration of oncology particularly is that the underlying genetic aberration of oncology generally helps in the process of identification of the disease.
Key Topics Covered:
1. Introduction to Orphan Drugs
2. Orphan Drug Designation Criteria: US, Europe & Asia
3. Orphan Drug Patent Protection & Market Exclusivity
4. Orphan Drug Regulatory Framework
5. Orphan Drug Reimbursement Policy: US, Europe & Asia
6. Global Orphan Cancer Drug Market Outlook
7. Orphan Cancer Drugs Clinical Pipeline by Phase, Country & Target Indications
8. Marketed Orphan Cancer Drugs
9. Suspended & Discontinued Orphan Cancer Drugs in Clinical Pipeline
10. Competitive Landscape
Following Information for Each Drug Profile is Covered in More than 400 Tables in Report:
- Drug Profile Overview
- Active Indication
- Phase of Development
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
For more information visit http://www.researchandmarkets.com/research/ftjrts/global_orphan
